This content is from: Premium Hedge Funds Are Holding Their Breath on This Biopharma IPO Several prominent hedge funds disclosed sizable stakes in PepGen, which went public earlier this month. By Stephen Taub May 23, 2022
This content is from: Premium Tiger Global Changes Up Its Private Market Strategy One of the most active venture capital investors is now emphasizing earlier-stage companies. By Stephen Taub March 14, 2022
This content is from: Portfolio SPACs Are Sputtering. Desperate New Terms Could Send Them Into a Death Spiral. Bankers, lawyers, and sponsors all said, “It’s different this time.” But it wasn’t. By Michelle Celarier May 16, 2022
This content is from: Premium Tesla Attracts Major Hedge Funds Several prominent firms established large stakes in the electric vehicle maker in the first quarter. By Stephen Taub May 18, 2022
This content is from: Premium Viking, Other Hedge Funds Eye Biopharma IPO Investors may not be too excited about the new issues market, however. By Stephen Taub January 04, 2022
Sponsored Renaissance Hires IB Co-Head Renaissance Capital has appointed John Hyman as co-head of investment banking and financing. October 11, 2011
